FR2983492B1 - Procede ex vivo de purge tumorale d'un echantillon biologique - Google Patents

Procede ex vivo de purge tumorale d'un echantillon biologique

Info

Publication number
FR2983492B1
FR2983492B1 FR1161202A FR1161202A FR2983492B1 FR 2983492 B1 FR2983492 B1 FR 2983492B1 FR 1161202 A FR1161202 A FR 1161202A FR 1161202 A FR1161202 A FR 1161202A FR 2983492 B1 FR2983492 B1 FR 2983492B1
Authority
FR
France
Prior art keywords
biological sample
vivo tumor
purge method
present
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1161202A
Other languages
English (en)
Other versions
FR2983492A1 (fr
Inventor
Gerard Quash
Mileidys Perez-Alea
Ismail Ceylan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADVANCED BIODESIGN
Original Assignee
ADVANCED BIODESIGN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADVANCED BIODESIGN filed Critical ADVANCED BIODESIGN
Priority to FR1161202A priority Critical patent/FR2983492B1/fr
Publication of FR2983492A1 publication Critical patent/FR2983492A1/fr
Application granted granted Critical
Publication of FR2983492B1 publication Critical patent/FR2983492B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention est relative à un procédé ex vivo de purge tumorale d'un échantillon biologique utilisant les aminothiolesters alpha, bêta-acétyléniques, de préférence le DIMATE. La présente invention trouve notamment une application dans le domaine de la médecine régénérative, de la greffe de moelle osseuse, et de la transfusion sanguine.
FR1161202A 2011-12-06 2011-12-06 Procede ex vivo de purge tumorale d'un echantillon biologique Active FR2983492B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1161202A FR2983492B1 (fr) 2011-12-06 2011-12-06 Procede ex vivo de purge tumorale d'un echantillon biologique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1161202A FR2983492B1 (fr) 2011-12-06 2011-12-06 Procede ex vivo de purge tumorale d'un echantillon biologique

Publications (2)

Publication Number Publication Date
FR2983492A1 FR2983492A1 (fr) 2013-06-07
FR2983492B1 true FR2983492B1 (fr) 2015-10-30

Family

ID=45888374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1161202A Active FR2983492B1 (fr) 2011-12-06 2011-12-06 Procede ex vivo de purge tumorale d'un echantillon biologique

Country Status (1)

Country Link
FR (1) FR2983492B1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109313201A (zh) * 2016-06-14 2019-02-05 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3047734B1 (fr) * 2016-02-17 2019-09-06 Advanced Biodesign Procede de preparation de composes aminothiolester et leurs sels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761606B1 (fr) * 1997-04-08 1999-05-14 Cird Galderma Utilisation de derives aminothiolesters dans le domaine pharmaceutique
FR2809727B1 (fr) * 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109313201A (zh) * 2016-06-14 2019-02-05 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
CN109313201B (zh) * 2016-06-14 2022-04-01 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体

Also Published As

Publication number Publication date
FR2983492A1 (fr) 2013-06-07

Similar Documents

Publication Publication Date Title
Li et al. Tissue-engineered bone immobilized with human adipose stem cells-derived exosomes promotes bone regeneration
AU2016265845B2 (en) Chimeric antigen receptor compositions
ES2526759T3 (es) Composición para inducir la regeneración tisular por activación de plasma rico en plaquetas (PRP) y procedimiento para fabricarla
US20230081191A1 (en) Conjoint therapies for immunomodulation
CA3040033A1 (fr) Double inhibiteurs de voies vista et pd -1
ES2562651T3 (es) Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
US20200054736A1 (en) Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy
Pitsillides et al. Cell labeling approaches for fluorescence‐based in vivo flow cytometry
MY160835A (en) System for purifying certain cell populations in blood or bone marrow by depleting others
TR201906285T4 (tr) İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.
BR112012024350A2 (pt) métodos para tratar paciente atraves da separação de ctcs, para capturar células de tumor circulantes (ctc) em fluido corporal e para descobrir fármacos, ctcs isoladas, filtro de captura de ctcs em fluido corporal e dispositivos extracorpóreos para a captura de ctcs em fluido corporal
US10414814B2 (en) Tumor-selective CTLA-4 antagonists
BR112020008537A2 (pt) inibidores duplos de vias da tim-3 e da pd-1
EP3208329A1 (fr) Procédé de production de cellules t gamma-delta, et produit pharmaceutique
FR2983492B1 (fr) Procede ex vivo de purge tumorale d'un echantillon biologique
EA201290245A1 (ru) Радиоактивно меченные pde10 лиганды
Kurwale et al. Role of bone marrow derived pluripotent stem cells in peripheral nerve repair in adult rats: A morphometric evaluation
Li et al. Li Zhang
US20230192846A1 (en) Anti-ror-2 antibodies and methods of use
JP2013515083A (ja) 癌幹細胞におけるａｌｄｈのインビボイメージング用アルデヒド
Tharp et al. Myeloid mechano-metabolic programming restricts anti-tumor immunity
EP3533801A1 (fr) Inhibiteur d'expression de synovioline comprenant une cellule souche mésenchymateuse ou un surnageant de culture
US11987606B2 (en) Compositions and methods for enhancing an immune response
US11083756B2 (en) Serum-free and xenogen-free human cardiac explant-derived stem cells and uses and methods for the production thereof
US20230340089A1 (en) Smc1a antibodies and uses thereof

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13